Margaglione M, Brancaccio V, Giuliani N, D'Andrea G, Cappucci G, Iannaccone L, Vecchione G, Grandone E, Di Minno G
IRCCS, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Ann Intern Med. 1998 Jul 15;129(2):89-93. doi: 10.7326/0003-4819-129-2-199807150-00003.
A mutation in the prothrombin gene (G-->A20210) has been associated with higher plasma prothrombin levels and an increased tendency for venous thrombosis.
To determine whether the prothrombin A20210 allele is independently associated with the occurrence of venous thrombosis.
Case-control study.
Two thrombosis centers in southern Italy.
281 consecutive patients with venous thrombosis confirmed by objective tests and 850 controls.
Medical history was collected on standardized questionnaires. The presence of prothrombin G-->A2020 and factor V Leiden mutations was determined by polymerase chain reaction. The presence of anticoagulant factors and prothrombin activity was determined by tests of function.
In 150 controls, increased prothrombin activity (P < 0.001) was associated with the prothrombin A20210 allele. This allele was more frequent in patients than in controls (8.01% compared with 2.29%; P < 0.001) and was associated with an increased risk for thrombosis (odds ratio, 3.88 [95% CI, 2.23 to 6.74]). The increased prevalence of this allele was independent of the presence of the factor V Leiden mutation. After adjustment for sex, age, arterial thrombosis, and factor V Leiden mutation, the risk was still significantly elevated (odds ratio, 3.13 [CI, 1.89 to 5.21]). Moreover, the overall prevalence of inherited coagulation abnormalities was significantly higher in patients with thrombosis of the lower extremities than in patients with thrombosis of the upper extremities (odds ratio, 3.77 [CI, 1.10 to 12.93]). Fourteen patients carried both the prothrombin G-->A20210 and factor V Leiden mutations.
The prothrombin A20210 allele is independently associated with the occurrence of venous thrombosis, particularly in patients with a history of thrombosis of the lower extremities.
凝血酶原基因(G→A20210)突变与血浆凝血酶原水平升高及静脉血栓形成倾向增加有关。
确定凝血酶原A20210等位基因是否与静脉血栓形成独立相关。
病例对照研究。
意大利南部的两个血栓形成中心。
281例经客观检查确诊的连续静脉血栓形成患者和850例对照。
通过标准化问卷收集病史。采用聚合酶链反应检测凝血酶原G→A2020和因子V莱顿突变的存在情况。通过功能检测确定抗凝因子和凝血酶原活性的存在情况。
在150例对照中,凝血酶原活性升高(P<0.001)与凝血酶原A20210等位基因相关。该等位基因在患者中比在对照中更常见(8.01%比2.29%;P<0.001),并且与血栓形成风险增加相关(比值比,3.88[95%CI,2.23至6.74])。该等位基因患病率增加与因子V莱顿突变的存在无关。在对性别、年龄、动脉血栓形成和因子V莱顿突变进行校正后,风险仍然显著升高(比值比,3.13[CI,1.89至5.21])。此外,下肢血栓形成患者遗传性凝血异常的总体患病率显著高于上肢血栓形成患者(比值比,3.77[CI,1.10至12.93])。14例患者同时携带凝血酶原G→A20210和因子V莱顿突变。
凝血酶原A20210等位基因与静脉血栓形成独立相关,尤其是在有下肢血栓形成病史的患者中。